Articles tagged "Cytomeglovirus"

2019 American Transplant Congress
Comparing the Rate of Opportunistic Infection after Renal Transplant between Alemtuzumab and Basiliximab for Induction Immunosuppression
J. A. Seaman¹, S. G. Westphal², F. Qiu³, D. Bremers⁴, D. Florescu⁵
¹College of Medicine, University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Nephrology, University of Nebraska Medical Center, Omaha, NE, ³Biostatistics, University of Nebraska Medical Center, Omaha, NE, ⁴Donate Life, Nebraska Medicine, Omaha, NE, ⁵Internal Medicine Division of Infectious Disease, University of Nebraska Medical Center, Omaha, NE
*Purpose: The aim of our study was to compare the outcomes one-year after renal transplant with a focus on opportunistic infections in patients who received…
2019 American Transplant Congress
Effect of Donor-Recipient Serologic CMV Matching on 1-Year Post-Lung Transplant Outcomes
H. Ehrenfeld, M. Manson, R. Yau
Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX
*Purpose: Cytomegalovirus (CMV) poses significant risks and complications in solid organ transplant (SOT) patients. The current CMV guidelines acknowledge CMV serologic mismatch transplants contribute to…
2019 American Transplant Congress
Preemptive Therapy is Cost Effective When Compared to Prophylaxis in Cytomegalovirus Donor Positive – Recipient Negative Liver Transplant Recipients
M. M. Wagener¹, D. J. Winston², R. R. Razonable³, G. M. Lyon III⁴, F. P. Silveira⁵, A. P. Limaye⁶, N. Singh¹
¹ID, U Pittsburgh and VAPHS, Pittsburgh, PA, ²ID, UCLA, Los Angeles, CA, ³ID, Mayo Clinic, Rochester, MN, ⁴ID, Emory, Atlanta, GA, ⁵ID, U Pittsburgh, Pittsburgh, PA, ⁶ID, U Washington, Seattle, WA
*Purpose: To compare the cost effectiveness of preemptive therapy (PET) vs prophylaxis for the prevention of cytomegalovirus (CMV) in high-risk donor seropositive/recipient seronegative (D+R-) liver…
2019 American Transplant Congress
The Association Of Frailty With Risk Of Cytomegalovirus And BK Infection
J. Norman¹, A. Gupta², A. Naik³, D. Cibrik², S. Norman³
¹Internal Medicine, Univ of Michigan Medical Ctr, Ann Arbor, MI, ²Internal Medicine/Nephrology, Kansas University Medical Center, Kansas City, KS, ³Internal Medicine/Nephrology, Univ of Michigan Medical Ctr, Ann Arbor, MI
*Purpose: Opportunistic infections are responsible for significant morbidity and mortality post-kidney transplant (KT). Recently, medical frailty has been recognized to increase the risk of death…
2019 American Transplant Congress
A Cytomegalovirus Antiviral Stewardship Program at a Large Transplant Center
M. Jorgenson¹, J. Descourouez¹, D. Felix¹, C. Saddler², J. Smith², D. Mandelbrot²
¹UW Health, Madison, WI, ²University of Wisconsin-Madison School of Medicine and Public Health, Madison, WI
*Purpose: The purpose of this study was to determine the feasibility and scope of a multidisciplinary cytomegalovirus Antiviral Stewardship Program.*Methods: The principles of antimicrobial stewardship…
2019 American Transplant Congress
Evolution of HHV6- and CMV-Specific T Cell Functional Responses and Immune Cell Populations after Kidney Transplant
A. Gil¹, M. Co², M. Calvo-Calle¹, J. Cruz¹, L. Stern¹, L. Gibson²
¹Pathology, University of Massachusetts Medical School, Worcester, MA, ²Medicine, University of Massachusetts Medical School, Worcester, MA
*Purpose: Human herpesvirus (HHV)-6 reactivation after solid organ or hematopoietic stem cell transplant has been associated with complications such as graft rejection and all-cause mortality.…
2019 American Transplant Congress
Evaluation of Rabbit Antithymocyte Globulin (rATG) Dosing and Incidence of Opportunistic Viral Infections in Kidney Transplant Recipients Using Tacrolimus (TAC), Mycophenolate (MPA) and Steroid Free Maintenance Immunosuppression
L. Von Stein, A. Leino, R. Amer, T. Pesavento, H. Winters
The Ohio State University Wexner Medical Center, Columbus, OH
*Purpose: There is limited literature evaluating rATG dosing and incidence of infection with TAC/MPA and early steroid withdrawal. This study evaluates rATG dosing and overall…
2019 American Transplant Congress
Healthcare Resource Utilization and Associated Costs of Cytomegalovirus Management among Solid Organ Transplant Recipients
W. Y. Cheng¹, P. Thompson-Leduc¹, H. Cheung¹, R. Avery², T. Bo³, S. Chavan³, M. Duh¹, I. Hirji³
¹Analysis Group, Inc., Boston, MA, ²Johns Hopkins University, Baltimore, MD, ³Shire, Cambridge, MA
*Purpose: Solid organ transplant (SOT) recipients who develop cytomegalovirus (CMV) infection and disease are at increased risk of morbidity. We quantified real-world healthcare resource utilization…
2019 American Transplant Congress
Differences in CMV-Specific CD4 T Cell Population in De Novo Kidney Transplant Recipients Treated with Everolimus-Based Regimen Compared to a Standard Tacrolimus-MPA Regimen: Results from ATHENA
I. A. Hauser¹, S. Marx¹, C. Sommerer¹, B. Suwelack¹, D. Dragun¹, O. Witzke¹, F. Lehner¹, I. Kroeger², M. Junge², F. Thaiss¹, B. Nashan¹, M. Sester¹
¹ATHENA, CMV Substudy Group, Germany, ²Novartis, Pharma GmbH, Germany
*Purpose: The ATHENA trial was designed to compare everolimus [EVR] in combination with tacrolimus [TAC] or cyclosporine A [CyA] vs. a standard regimen of mycophenolic…
2019 American Transplant Congress
Low-Dose Valacyclovir Prophylaxis for Cytomegalovirus Infection in Renal Transplant Recipients with Intermediate Risk
A. Velioglu¹, H. Arikan¹, E. Asicioglu¹, S. Alagoz², N. Seyahi², S. Tuglular¹, C. Ozener¹
¹Nephrology, Marmara University School of Medicine, İstanbul, Turkey, ²Nephrology, Istanbul University, Cerrahpasa Medical School, İstanbul, Turkey
*Purpose: According to recent guidelines ganciclovir or valganciclovir chemoprophylaxis is recommended for all kidney transplantation (KT) recipients (except for D-/R- serology) for preventing cytomegalovirus (CMV)…